Literature DB >> 19591220

Effect of blood group on idiopathic thrombotic thrombocytopenic purpura.

Lara Zuberi1, Durga Yerasuri, Philip Kuriakose.   

Abstract

Thrombotic thrombocytopenic purpura (TTP) is a condition caused by deficiency of ADAMTS13 resulting in accumulation of ultra large Von Willebrand factor multimers (ULVWF), leading to micro thrombi in multiple organs. The varying susceptibilities of blood group antigens to ADAMTS13 have been demonstrated. A and B antigens are protective of VWF; and VWF purified from blood group O individuals has been shown to be cleaved faster by ADAMTS13 compared to VWF from blood group AB individuals. We proposed that there may be a difference in the incidence of blood groups in TTP patients compared with the general population. We felt this to be important for a life-threatening disease with poorly understood epidemiology. We report a retrospective analysis of 74 patients presenting from 1993 to 2008 with idiopathic TTP. We studied the incidence across various blood groups and also estimated the recurrence and mortality in each group. The incidence of various blood groups were as follows: O 36%, A 36%, B 25%, and AB 2%, compared with expected frequencies in the Detroit area: O 44%, A 33% B 20%, and AB 3%. There was a trend of lower than expected frequency of blood group O. There were 24 recurrences and 14 deaths, uniform across blood groups. We hypothesized that there may be an association between blood groups and the risk of TTP; however the differences in our study were not statistically significant. Recurrence and disease specific mortality did not appear to be impacted by blood group.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19591220     DOI: 10.1002/jca.20202

Source DB:  PubMed          Journal:  J Clin Apher        ISSN: 0733-2459            Impact factor:   2.821


  5 in total

Review 1.  Thrombotic thrombocytopenic purpura: a review of the literature in the light of our experience with plasma exchange.

Authors:  Claudia Rizzo; Sergio Rizzo; Elisabetta Scirè; Danilo Di Bona; Carlo Ingrassia; Giovanni Franco; Roberto Bono; Gerlando Quintini; Calogero Caruso
Journal:  Blood Transfus       Date:  2012-06-27       Impact factor: 3.443

2.  Blood group O and black race are independent risk factors for thrombotic thrombocytopenic purpura associated with severe ADAMTS13 deficiency.

Authors:  Deirdra R Terrell; David G Motto; Johanna A Kremer Hovinga; Bernhard Lämmle; James N George; Sara K Vesely
Journal:  Transfusion       Date:  2011-04-06       Impact factor: 3.157

3.  Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura.

Authors:  Lova Sun; Johnathan Mack; Ang Li; Justine Ryu; Vivek A Upadhyay; Lynne Uhl; Richard M Kaufman; Christopher P Stowell; Walter S Dzik; Robert S Makar; Pavan K Bendapudi
Journal:  Blood Adv       Date:  2019-05-14

Review 4.  Severe Thrombotic Thrombocytopenic Purpura (TTP) with Organ Failure in Critically Ill Patients.

Authors:  Sofiane Fodil; Lara Zafrani
Journal:  J Clin Med       Date:  2022-02-19       Impact factor: 4.241

5.  Thrombotic thrombocytopenic purpura secondary to ABO group incompatible blood transfusion in a patient after cardiac surgery.

Authors:  Yalcin Solak; Nedim Yilmaz Selcuk; Abduzhappar Gaipov; Ramazan Ucar; Zeynep Biyik; Kadir Acar
Journal:  Indian J Crit Care Med       Date:  2013-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.